(Boursier.com) — bioMerieux fell further by 1.2% to 86.50 euros on Thursday on the Paris market. The in vitro diagnostics specialist warned yesterday that its results should drop in 2022 in the event of a slowdown in demand for its Covid-19 tests if the pandemic becomes endemic… Management is thus counting on an operating result 2022 current contribution of between 530 and 610 million euros, at current exchange rates, for a turnover which should fall by 3 to 7% at constant exchange rates and perimeter.
Among the latest analysts’ opinions, Midcap Partners lowered its target from 141.5 to 134 euros while remaining on the buy side and Invest Securities reduced its price target from 145 to 116 euros while also remaining on the buy side. . Stifel (‘buy’) said yesterday that the company had released a strong set of results for its 2021 financial year. “However, the 2022 guidance is well below consensus.”
©2022 Boursier.com